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Abstract
Background: The aim of the present work was to analyse the impact of mild hypofractionated radiotherapy (RT) of
infra-supraclavicular lymph nodes after axillary dissection on late toxicity.
Methods: From 2007 to 2012, 100 females affected by breast cancer (pT1- T4, pN1-3, pMx) were treated with
conservative surgery, Axillary Node Dissection (AND) and loco-regional radiotherapy (whole breast plus
infra-supraclavicular fossa). Axillary lymph nodes metastases were confirmed in all women. The median age at
diagnosis was 60 years (range 34–83). Tumors were classified according to molecular characteristics: luminal-A
59 pts (59 %), luminal-B 24 pts (24 %), basal-like 10 pts (10 %), Her-2 like 7 pts (7 %). 82 pts (82 %) received
hormonal therapy, 9 pts (9 %) neo-adjuvant chemotherapy, 81pts (81 %) adjuvant chemotherapy. All patients
received a mild hypofractionated RT: 46 Gy in 20 fractions 4 times a week to whole breast and infra-
supraclavicular fossa plus an additional weekly dose of 1,2 Gy to the lumpectomy area. The disease control
and treatment related toxicity were analysed in follow-up visits. The extent of lymphedema was analysed by
experts in Oncological Rehabilitation.
Results: Within a median follow-up of 50 months (range 19–82), 6 (6 %) pts died, 1 pt (1 %) had local
progression disease, 2 pts (2 %) developed distant metastasis and 1 subject (1 %) presented both. In all
patients the acute toxicity was mainly represented by erythema and patchy moist desquamation. At the end
of radiotherapy 27 pts (27 %) presented lymphedema, but only 10 cases (10 %) seemed to be correlated to
radiotherapy. None of the patients showed a severe damage to the brachial plexus, and the described cases
of paresthesias could not definitely be attributed to RT. We did not observe symptomatic pneumonitis.
Conclusions: Irradiation of infra-supraclavicular nodes with a mild hypofractionated schedule can be a safe
and effective treatment without evidence of a significant increase of lymphedema appearance radiotherapy
related.
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Background
In high-risk node-positive women with breast cancer,
national and international guidelines (AIRO/NCCN/
DEGRO) recommended to extend radiotherapy to lymph
nodal area (apex axilla - III level and/or supraclavicular re-
gions) after axillary dissection to improve loco-regional
control and survival, especially in the presence of add-
itional clinical and biological risk factors [1–4]. The stand-
ard given dose post conservative surgery remains 50 Gy in
25 fractions over 5 weeks and it is recommended a boost
to the tumor bed to further improve the local control [5].
Several randomized trials proved that in selected low-risk
patients, shorter treatment regimens (3 to 4 weeks) with a
hypofractionated schedule may be safe and effective with
comparable medical outcome and cosmesis [6, 7]. A task
force group endorsed by the American Society for Radi-
ation Oncology (ASTRO) asserted that data are now suffi-
cient to support the use of hypofractionated whole breast
irradiation (HF-WBI) for selected patients with early-stage
breast cancer [8] and recently the same association has
recommended the administration of such therapeutic
schedule [9]. Published data supportive of hypo-
fractionated schedules are limited to breast irradiation and
only few clinical trials are available on regional lymph
node irradiation with short schemes [10]. The hypo-
fractionated loco-regional radiotherapy scheme used in
our Institute is not particularly compressed in time but
provides a smaller number of fractions (20 versus 25), dur-
ing which the boost to the tumor bed is simultaneously
administered once-a-week, reducing the patient accesses
[11]. This is a retrospective study about one hundred con-
secutive patients treated with mild hypofractionated locor-
egional radiotherapy. The aim of the present work was to
analyse the impact on late toxicity of this hypofractionated
scheme in order to assess safety and efficacy in infrasupra-
clavicular area.
Methods
From 2007 to 2012, one hundred patients affected by
breast cancer were treated with conservative surgery, ax-
illary node dissection (AND) and loco-regional (whole
breast plus infra-supraclavicular fossa) hypofractionated
RT. The median age at diagnosis was 60 years (range
34–83). Histology was ductal carcinoma in 76 patients
(76 %). Characteristics of patients are shown in Table 1.
Tumors were classified according to molecular charac-
teristic as shown in Table 2. Axillary lymph nodes me-
tastasis were confirmed in all women (81 patients post
conservative surgery and 9 patients at diagnosis, before
neo-adjuvant chemotherapy). Patients received systemic
therapy: hormonal in 82 patients (82 %), neo-adjuvant
chemotherapy in 9 patients (9 %), adjuvant chemotherapy
in 81 patients (81 %). All the administered chemotherapy
schedules contained anthracycline derivatives and taxanes.
In agreement with several randomized phase III trials
which have shown to improve local control with mild side
effects and acceptable cosmetic outcome [5] in our center
all the patients receive a boost dose. The selected group of
patients examined in this analysis received hypofractio-
nated RT with concomitant boost as described in detail in
a previous published experience [11], Our treatment
schedule was 46 Gy in 20 fractions 4 times a week to
Table 1 Patients’ characteristics
Characteristic N %
Age
<50 24 24 %
50-59 23 23 %
>60 53 53 %
Histology
DCI 75 75 %
LCI 15 15 %
Others 10 10 %
Pathological tumor stage
pTis 2 2 %
pT1 51 51 %
pT2 38 38 %
pT3 2 2 %
pT4 2 2 %
Not evaluable 5 5 %
Pathological nodal stage
pN0 9 9 %
pN1 25 25 %
pN2 43 43 %
pN3 23 23 %
Grading
G1 4 4 %
G2 54 54 %
G3 38 38 %
Not evaluable 4 4 %
Ki67
≤14 % 27 27 %
>14 % 71 71 %
Not evaluated 2 2 %
DCI ductal carcinoma invasive, LCI lobular carcinoma invasive
Table 2 Molecular characteristics of patients
Molecular subtype N %
Luminal A 59 59 %
Luminal B 24 24 %
C-erb +++ 7 7 %
Basal like 10 10 %
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whole breast and infra-supraclavicular fossa (from Monday
to Friday with a day off on Wednesday) with concomitant
additional weekly dose of 1,2 Gy (preferibly delivered on
Monday) to the lumpectomy area (total boost dose of 6 Gy
in 5 fractions once a week). As reported by our previous
paper, using the Linear-Quadratic cell survival model we
assumed that 46Gy in 2.3 Gy fractions is equivalent to
50Gy in 2.0 Gy fractions as shown in Table 3 [11]. The four
fractions per week schedule is commonly used in our De-
partment in order to optimize the clinical and dosimetric
activities, by also allowing an easier integration of palliative
treatments [11–13]. Most treatments (81 %) were delivered
by linear accelerator Varian Clinac 2100CD (RX, 6–15
MV), and the remaining 19 % by Tomotherapy Hi-Art®
System (Accuray®, RX 6MV) when it was necessary to im-
prove coverage of the target or minimize dose to normal
tissue in selected patients in which a steep dose gradient
was required. A planning computed tomography (CT GE
Lightspeed Ultra) scan was made for each patient, posi-
tioned on a wing-board with both arms raised above the
head. Patients were scanned from the level of the larynx to
the level of the upper abdomen, including both lungs, with
a scan thickness and index of 5 mm [11]. Four tattoos were
made on the thoracic skin to allow the repositioning of the
patient during treatment sessions. The whole breast clin-
ical target volume (WB-CTV) included the glandular
breast tissue of the ipsilateral breast. The WB-CTV did
not extend into the pectoralis major, nor the ribs, and did
not include the skin [11]. The three-dimensional tissue vol-
umes containing the supraclavicular (SCV) infraclavicular
(IFV) and III level lymph nodes were defined on CT scans
by using readily identifiable anatomic landmarks on the
guide of two published papers (Table 4) [14]. In patients
treated by linear accelerator (81 %), whole breast radiation
was delivered by opposed tangential beams and infra-
supraclavicular fossa by two or more opposing fields (main
beam energy: 6 MV and, when it is necessary to improve
target coverage, 15 MV). The gantry angles, the use of
multileaf collimator, wedges and additional subfields were
employed to achieve optimal dose distribution and max-
imal organ at risk avoidance (heart, left anterior descend-
ing coronary artery, ipsilateral lung, esophagus, thyroid
and spinal cord). Constraints for the organs at risk are
shown in Table 5, overdosages were limited within 5 %,
this means that global Dmax is mantained lower than
105 % and this is possible using sub fields with MLC closed
on overdosage regions. Tomotherapy Hi-Art® treatments
were delivered using a 0.403 pitch, Modulator Factor (MF)
ranging between 1.5–4, field dimension 2.5 cm. It was im-
possible to exclude the brachial plexus from the radiation
fields due to its proximity to the lymph nodes region.
Treatment Planning was performed in order to give 95 %
of the prescribed dose to PTV; in three-dimensional (3D)
conformal Radiotherapy an Eclipse v.7.3.10 Varian Treat-
ment Planning System was used while Helical tomotherapy
planning was performed with the HI-Art® Tomotherapy in-
verse planning system (Madison, WI, USA). Portal films
were taken at least once during the first treatment day and
compared to digitally reconstructed radiographs (DRR)
and simulator images to ensure accurate set up. In
Tomotherapy a pre-treatment daily image guidance with
megavoltage (MV) CT scan was performed. After matching
with the kilovoltage planning CT, corrections for transla-
tions and rotation around longitudinal axis (roll) were done.
The disease control and treatment-related toxicity were
analysed in follow-up visits, performed at 6, 12 months
after therapy and, subsequently, annually. Particular atten-
tion was paid to late side effects correlated to radiation of
infra-supraclavicular fossa. The extent of lymphedema was
analysed at the department of Oncological Rehabilitation of
our Institute, by measuring upper limbs circumference at
two different locations obtained 10 cm above and below
the antecubital fossa in both upper extremities and compar-
ing the values with those of the contralateral arm, as sug-
gested by other authors [15]. Mild, moderate and severe
arm lymphedema were defined as a difference of 0.5–2 cm,
Table 3 BED comparison between standard and explored RT schedule [11]
RT schedule BED tumor control α/β 4 BED acute effects α/β 10 BED fibrosis α/β 1.7 BED vascular damage α/β 2.5
W.B. = whole breast W.B. B.S W.B. B.S W.B. B.S W.B. B.S
B.S. = tumor bed side
60 Gy/30 F/6 W 75 90 60 72 109 131 90 108
(50 Gy + 10 Gy seq.boost)
52 Gy/20/F/5 W
(46 Gy + 6 Gy cc.boost)
72 87 57 66 108 135 88 108
UK START TRIAL A 75 75 55 55 120 120 95 95
41.6 Gy/13 F/5 W
UK START TRIAL A 68 68 51 51 108 108 86 86
39 Gy/13 F/5 W
boost concomitant boost, seq.boost sequential boost, F fractions, W weeks
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2.1–3 cm and >3 cm respectively, in the circumference at
one or more measurement sites between the treated and
untreated sides [15]. Patients were followed by Oncological
Rehabilitation Unit to appearance of lymphedema accord-
ing to its severity.
Results
Within a median follow-up of 50 months (range 19–82),
6 patients (6 %) died, one patient (1 %) had local pro-
gression disease, 2 patients (2 %) developed distant me-
tastasis and 1 (1 %) subject presented both. In all
patients the acute toxicity, according to the RTOG/
EORTC classification [16], was mainly represented by
erythema and patchy moist desquamation. In 27 patients
(27 %) a lymphedema was recorded during the visit at
the Department of Oncological Rehabilitation of our in-
stitute: 15 cases (15 %) as a likely consequence of
chemotherapy and surgery because they appeared before
radiotherapy. In only three cases, a preexisting lymph-
edema was worsened by radiotherapy. In 12 patients
(12 %) it appeared after the end of radiotherapy: in 2 pa-
tients as a result of disease progression to the lymph
nodes, in the remaining 10 patients appears to be related
to radiotherapy. The time of onset of lymphedema in the
latter 10 cases was very variable (from 1 to 48 months
from the end of radiotherapy). The cases of radio in-
duced lymphedema were classified as follows: 4 mild, 2
moderate and 4 severe. These patients were treated with
manual lymph drainage and compression therapy. Post-RT,
three patients showed paresthesias of upper limbs, two
bilaterally, already present before starting radiation
treatment, the last one ipsilateral, which resolved spontan-
eously in few months. All patients received chemotherapy
regimens containing taxanes, of which paresthesias are one
of the side effects. Treatment was generally well tolerated:
a limited number of severe lymphedema (4 %), none of the
patients showed a severe damage to the brachial plexus,
the described cases of paresthesias could not definitely be
attributed to RT and we did not observed symptomatic
pneumonitis.
Discussion
The aim of the present work is to investigate the out-
comes of a mild HF-WBI for the treatment of breast
cancer when delivered to women who need irradiation
to the infra-supraclavicular lymph nodal region. Our re-
sults seem to suggest that this hypofractionated schedule
to the breast and the regional nodes is as effective as a
standard RT regimen in the absence a significant in-
crease of side effects. This evidence is of note since
many concerns emerge when an altered fractionated
regimen is proposed for the irradiation of locoregional
node areas. As reported in the literature, the irradiation
of the lymph node area may increase the risk of side ef-
fects such as radiation pneumonitis, lymphedema and
brachial plexopathy. Since acute and late side effects are
correlated to the volume of irradiated parenchyma, re-
gional nodal radiotherapy can increase the pneumonitis
rates (1.3 % vs 0.2 %) [17]. In order to reduce the risk of
radio-induced pneumonitis, internationally approved
protocols should be strictly applied [18]. Lymphedema
may represent a standard complication after any axillary
Table 4 Regional Nodal Contours: anatomical boundaries [14]
Anteriorly Posteriorly Superiorly Inferiorly Medially Laterally
SCV bounded by the deep surface
of the sternocleidomastoid
and the deep cervical fascia
Lat: the anterior and
medial borders of the
anterior scalene muscle.
the posterior border
was defined by the
subclavian artery
lateral edge of the
trachea excluding the
thyroid gland and thyroid
cartilage superiorly
Med: medially to the
carotid artery and internal
jugular vein
IFV the deep surface of the
pectoralis major muscle













SCV supraclavicular fossa, IFV infraclavicular fossa
Table 5 Constraints for organs at risk in adjuvant radiotherapy of early breast cancer
Organ at risk Normofractionation 2 Gy per fraction\5fr\week Hypofractionated schedule 2,3 Gy per fraction\4 fr\week
LADCA V20Gy = 0 % V19Gy = 0 %
Heart V20Gy = 10 % V40Gy =5 % V19Gy = 0 %
Ipsilateral Lung V20Gy = 25 % (exclusive periclavicular LN) V19Gy = 25 % (exclusive periclavicular LN)
V20Gy = 35 % (inclusive periclavicular LN) V19Gy = 35 % (inclusive periclavicular LN)
Spinal cord Max 45 Gy Max 42 Gy
LADCA left anterior descending coronary artery, LN lymph nodes
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surgery. Its incidence can be difficult to define, as no
standardized definition of lymphedema exists. The onset
of lymphedema is related different causes including the
extension of axillary dissection (5–15 % after dissection,
1–3 % after sentinel node biopsy), obesity, the associ-
ation with chemotherapy and RT delivery [19–23]. Shah
et al., provides the incidence of lymphedema according
to the extent of RT after dissection, reporting a rate from
2–35 % after breast irradiation and an increased incidence
to 9–65 % in the case of loco-regional irradiation [20]. The
different findings of lymphedema may be related not only
to individual clinical situations and radiation techniques
applied (extension of treatment volumes, type of planning,
others) but also to the different methods of evaluation and
classification used. Inter-limb circumferential discrepancy
has been the most widely used outcome measure. More-
over, brachial plexopathy is a major concern with loco-
regional RT: the induced damage may be related to dose
per fraction, total dose, and volume irradiated. Using
standard fractionation schedule (50Gy/25fr) the rates of
brachial plexopathy are less than 5 % [10]. In recent years
several schemes of hypofractionated WBI were developed
and tested in randomized trials. The results with long-term
follow-up demonstrated that the adoption of a shorter
schedule may be safe and effective with comparable med-
ical outcome and cosmesis to the standard irradiation: no
statically significant differences both in local control and
aesthetic result emerged in women who received the
standard or the hypofractionated breast radiation [6, 7].
However, few data are still available as regards the late
effects of hypofractionated radiotherapy when extended
to the regional lymph nodes. A recent update of START
A and START B evaluated the loco-regional RT in a lim-
ited group of patients and neither the 5 week nor the
3 week treatment developed significantly worse normal
tissue impacts: the assessments of arm and shoulder ef-
fects showed no evidence of a detrimental effect for the
hypofractionated schedules [7]. In 2011 Yarnolds et al.
already showed no radio-induced brachial plexus toxicity
after hypofractionated irradiation of the axilla and/or
supraclavicular fossa. Those Authors stated that the
START B regimen (40 Gy in 15 fractions/3 weeks) is
equivalent to 47 Gy in 2.0-Gy fractions if the α/β value for
brachial plexus is 2.0 Gy or to 49 Gy in 2.0-Gy fractions, if
α/β = 1.0 Gy [24]. Haffty and Buchholz commented on the
absence of side effects in the small group of patients
(116pts of 2215, 7 %) enrolled in the START B trial and
receiving regional hypofractionated RT: they confirmed
that these results are consistent with modelling of normal
tissue effects, which predicts that 40 Gy in 15 fractions
should be as safe as the standard scheme for all normal
tissues [25]. The results of several randomized studies
demonstrated the feasibility and effectiveness of the hypo-
fractionated WBI. Although limited, other data collected
during hypofractionated regional nodes irradiation did not
reveal increased toxicity as compared to standard fraction-
ation RNI [10]. Badiyan N. et al. reviewed prospective and
randomized data to analyse the efficacy and toxicity of
hypofractionated radiation schedules in breast cancer with
RNI to the axilla and supraclavicular regions. They noted
that RNI with standard fractionation is associated with in-
creased toxicity compared to WBI alone but current data
do not support an increased rate of toxicity with hypofrac-
tionated RNI compared with standard fractionation RNI
[10]. The outcomes of our investigation seem to confirm
what emerges from the literature: patients treated with
hypofractionated RT (46Gy in 20 fractions with 4 times a
week) to the whole breast and infra-supraclavicular fossa
(plus once weekly concomitant boost dose of 1,2 Gy to
the lumpectomy area) did not show a higher rate of side
effects, in 10 patients the lymphedema was radio induced,
which only 4 severe. We observed no symptomatic pneu-
monitis, no radiation-related damage to the brachial
plexus and only 11 % of lymphedema. The favorable re-
sults obtained with this fractionation can be the basis for
investigating new radiation schemes with a smaller num-
ber of fractions administered in reduced times.
Conclusions
Mild hypofractionated WBI delivered in 20 fractions
represents a safe and effective treatment for the infrasu-
praclavicular node areas. ASTRO board reported that
shorter treatment schedules can significantly benefit pa-
tients in terms of convenience, acceptance of therapy,
and cost. They suggest to do not initiate whole-breast
radiation therapy as a part of breast conservation ther-
apy in women age ≥50 with early-stage invasive breast
cancer without considering shorter treatment schedule
[9]. The limited experience available on hypofractionated
scheme extended to lymph nodes do not seem to show
an increased toxicity. In our department the adoption of
this mild hypofractionated loco-regional radiation sched-
ule in the context of a policy of gradual reduction of the
numbers of the fractions has shown to be safe when de-
livered on locoregional nodal areas. This preliminary evi-
dence should be further investigated and confirmed by
large-scale prospective studies.
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